Intravenous Immunoglobulin (IVIg) market 2019 by Type, Share, Growth, Trends and Forecast To 2023

Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies by the human body to fight out the immune deficiency, and the ensuing infectious attacks.

Immunodeficiency disorder could be a hereditary issue (Primary disorders), or caused due to the exposure to infections, mainly through bodily fluids, along with the cancer drugs and chemotherapy, aging is one of the key risk factors too that could put someone at higher risk of a damaged immune system.

People nowadays are increasingly adopting heady & unhealthy lifestyles which mirror the prevalence of damaged immune system. Factors such as immense stress, lack of good quality sleep, inadequate & improper diet and sedentary lifestyle are fuelling the prevalence of immunodeficiency disorder and therefore, predominantly driving the growth of the market.  

Considering the kind of the growth the market perceives currently; Market Research Future (MRFR) has recently published a study report giving out the complete market forecast up to 2023. In its analysis, MRFR asserts that the global intravenous immunoglobulin market growing further will reach USD 8337.2 MN by 2023, registering approximately 5.9% CAGR from 2017 to 2023. 

The augmenting demand for alternate immunoglobulin replacement therapies, increasing R&D funding, rapidly developing healthcare infrastructure and increasing healthcare expenditures are major driving forces for the market growth.  Technological advancements transpired in medical science, are fostering the growth of the market exponentially, bringing up new treatment procedures, & medications in the field of IVIg.

Additionally, factors such as growing population and geriatric populace worldwide are fostering market growth. Rapidly developing economy worldwide is providing impetus to the market growth, enabling access to the quality life & improved healthcare. Substantial investments made in the development of IVIg, by the key market players are paying off well, driving the growth of the market.

On the flip side, factors such as low awareness among people about the availability of treatment, the high cost of IVIg management along with the skepticism towards the advancement & efficacies of these treatments among the patients are likely to impede the growth of the Intravenous Immunoglobulin market.

Global Intravenous Immunoglobulin Market – Competitive Landscape

Fiercely competitive, the global IVIg market appears to be fragmented due to the presence of several large and small players. These players acquire small yet promising companies to expand their reach in the emerging markets, focusing on improving their market performance. The acquisition of local manufactures by multinational companies makes the market structure look dynamic. Strategies such as product innovations and technologies are creating strong investment opportunities for the players.

Major Players:

Key players leading the global IVIg market include Baxter (US), BDI Pharma (US), Abeona Therapeutics (US), China Biologic Products, Inc. (China), Grifols Inc. (Spain), Biotest AG. (Germany), CSL Behring (US), Octapharma (Switzerland), Kedrion S.p.A (US), and Shire (Republic of Ireland) among others.

Industry, Innovation & Related News

March 28, 2019 --- CSL Behring (the US), a leading global biotherapeutics and biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products announced the receiving of an approval from Japan's Ministry of Health, Labour and Welfare has for two of its immunoglobulin therapies - named Hizentra and Privigen for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy.

Out of these, Hizentra which was previously approved for the treatment of primary immunodeficiency (PI) is now Japan's first and only subcutaneous immunoglobulin (SCIG) treatment approved for maintenance therapy to treat CIDP.  Privigen, an intravenous immunoglobulin (IVIG), is now approved for both acute and maintenance treatment of CIDP in Japan.  

 Intravenous Immunoglobulin (IVIg) Market information, by type (IgA, IgD, IgE, IgG, IgM), by Appliaction (Chronic inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia, Multifocal Motor Neuropathy, Immunodeficiency diseases, Primary Humoral Immunodeficiency, Myasthenia Gravis, Guillain-Barre syndrome, Kawasaki disease, ITP, and others) - Forecast to 2023: https://www.marketresearchfuture.com/reports/intravenous-immunoglobulin-market-3137